23andMe Announces Poster Presentations on 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2023 Annual Meeting
28 September 2023 - 6:05AM
23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human
genetics and biopharmaceutical company, today announced two poster
presentations on 23ME-00610, an investigational antibody targeting
CD200R1, at the Society for Immunotherapy of Cancer’s (SITC) 38th
Annual Meeting in San Diego, CA, taking place November 1-5, 2023.
The presentations will include updated safety and
efficacy data from the Phase 1 portion of the ongoing Phase 1/2a
study of 23ME-00610 in patients with advanced solid malignancies.
The Company will also present data on the pharmacokinetics,
pharmacodynamics and safety data supporting the Phase 1 and Phase 2
dose selection for the 23ME-00610 study.
Title: First-in-Class anti-CD200R1
Antibody 23ME-00610 in Patients with AdvancedSolid Malignancies:
Updated Phase 1 ResultsSession: Annual Meeting
Regular Poster Abstract PresenterAbstract/Poster
Number: 619Location: Posters are
presented in Exhibit Halls A and B1 (poster will also be available
to view under the investors section of the Company’s website at
investors.23andme.com).Date and Time: Friday, Nov.
3, 2023; Poster Hall Hours: 9 a.m.–7 p.m. PT
Title: Phase 1/2a Dose Selection
of 23ME-00610, a First-in-Class anti-CD200R1 Antibody, inPatients
with Advanced Solid MalignanciesSession: Annual
Meeting Regular Poster Abstract PresenterAbstract/Poster
Number: 609Location: Posters are
presented in Exhibit Halls A and B1 (poster will also be available
to view under the investors section of the Company’s website at
investors.23andme.com).Date and Time: Friday, Nov.
3, 2023; Poster Hall Hours: 9 a.m.–7 p.m. PT
About 23ME-0061023ME-00610 is a
high-affinity, fully humanized monoclonal antibody that is designed
to bind to CD200R1 and prevent the interaction of CD200R1 with
CD200. The CD200–CD200R1 axis is an immunological checkpoint that
plays a pivotal role in maintenance of immune tolerance. CD200R1 is
an inhibitory receptor expressed on T cells and myeloid cells while
CD200, the ligand for CD200R1, is highly expressed on certain
tumors. In preclinical studies, binding of tumor-associated CD200
to CD200R1 leads to immune suppression and decreased immune cell
killing of cancer cells. Preclinical data indicate that this
mechanism has the potential to restore the ability for both T-cells
and myeloid cells to kill cancer cells. Clinical trials registry
(clinicaltrials.gov): NCT05199272.
About 23andMe23andMe is a
genetics-led consumer healthcare and biopharmaceutical company
empowering a healthier future. For more information, please visit
www.23andMe.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, including, without limitation, statements
regarding the future performance of 23andMe’s businesses in
consumer genetics and therapeutics and the growth and potential of
its proprietary research platform. All statements, other than
statements of historical fact, included or incorporated in this
press release, including statements regarding 23andMe’s products,
strategy, financial position, funding for continued operations,
cash reserves, projected costs, plans, potential future
collaborations, therapeutics development, product development and
launches, the successful commercialization and market acceptance of
new products and objectives of management, are forward-looking
statements. The words "believes," "anticipates," "estimates,"
"plans," "expects," "intends," "may," "could," "should,"
"potential," "likely," "projects," “predicts,” "continue," "will,"
“schedule,” and "would" or, in each case, their negative or other
variations or comparable terminology, are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. These forward-looking
statements are predictions based on 23andMe’s current expectations
and projections about future events and various assumptions.
23andMe cannot guarantee that it will actually achieve the plans,
intentions, or expectations disclosed in its forward-looking
statements and you should not place undue reliance on 23andMe’s
forward-looking statements. These forward-looking statements
involve a number of risks, uncertainties (many of which are beyond
the control of 23andMe), or other assumptions that may cause actual
results or performance to differ materially from those expressed or
implied by these forward-looking statements. The forward-looking
statements contained herein are also subject generally to other
risks and uncertainties that are described from time to time in the
Company’s filings with the Securities and Exchange Commission,
including under Item 1A, “Risk Factors” in the Company’s most
recent Annual Report on Form 10-K, as filed with the Securities and
Exchange Commission, and as revised and updated by our Quarterly
Reports on Form 10-Q and Current Reports on Form 8-K. The
statements made herein are made as of the date of this press
release and, except as may be required by law, 23andMe undertakes
no obligation to update them, whether as a result of new
information, developments, or otherwise.
Contacts: Investor Relations
Contact: investors@23andMe.comMedia Contact: press@23andMe.com
23andMe (NASDAQ:ME)
Historical Stock Chart
From Apr 2024 to May 2024
23andMe (NASDAQ:ME)
Historical Stock Chart
From May 2023 to May 2024